Binge eating is a serious problem and researchers may have found a way to supress it using a drug already approved by the FDA – a Serotonin 2C Agonist.
While binge eating affects about 10 percent of adults in the United States, the neurobiological basis of the disease is unclear. Researchers at the USDA/ARS Children’s Nutrition Research Center at Baylor College of Medicine and Texas Children’s Hospital found that certain neural circuits have the ability to inhibit binge-like eating behavior. Their report appeared in the journal Biological Psychiatry.
According to NEDA (National Eating Disorders Association):
“Binge eating disorder (BED) is an eating disorder characterized by recurrent episodes of eating large quantities of food (often very quickly and to the point of discomfort); a feeling of a loss of control during the binge; experiencing shame, distress or guilt afterwards; and not regularly using unhealthy compensatory measures (e.g., purging) to counter the binge eating. Binge eating disorder is a severe, life-threatening and treatable eating disorder. Common aspects of BED include functional impairment, suicide risk and a high frequency of co-occurring psychiatric disorders.”
Dr. Yong Xu, associate professor of pediatrics at Baylor and senior author of the paper, said “Human literature suggests that dysfunction of the serotonin system or dopamine system in the brain may be associated with developing binge-like eating behavior. However, mechanistically, there’s no direct evidence to show how this system affects behavior.”
In this study, Xu and colleagues identified a neural circuit where a group of serotonin neurons project to and activate dopamine neurons. They showed that activation of this circuit can inhibit binge-like eating behavior in mice.
In addition, since there are 14 potential receptors that can mediate complex effects of serotonin in the body, Xu and colleagues identified a specific receptor that is important in binge-like eating behavior.
They determined that the serotonin 2C receptor, which is expressed by dopamine neurons, is important in suppressing binge eating.
Xu noted that an FDA-approved drug, a serotonin 2C agonist, is currently being used as a treatment for overweight and obese adults and could potentially be repurposed to suppress binge eating in adults.
Others who took part in the study include Pingwen Xu, Yanlin He, Xuehong Cao, Xiaofeng Yan, Kenji Saito, Chunmei Wang, Yongjie Yang, Antentor Hinton Jr., Gang Shu, and Qi Wu with Baylor; Liangru Zhu with Baylor and Huazhong University of Sciences & Technology in China; Martin G. Myers Jr. with the University of Michigan; Lourdes Valencia-Torres and Lora K. Heisler with Rowett Institute of Nutrition and Health in Aberdeen; and Qingchun Tong with the University of Texas Health Science Center at Houston.
Funding for the study came from the National Institutes of Health (R01DK093587 and R01DK101379; R01DK092605; R01DK078056), the Naman Family Fund for Basic Research, the Curtis Hankamer Basic Research Fund, the American Diabetes Association (#7-13-JF-61 and #1-15-BS-184 ), the American Heart Association postdoctoral fellowship, Wellcome Trust (WT098012) and BBSRC (BB/K001418/1).
Source: Baylor College of Medicine
Journal: Biological Psychiatry
Funder: National Institutes of Health, Naman Family Fund for Basic Research, Curtis Hankamer Basic Research Fund, American Diabetes Association